ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche has licensed rights to PTC Therapeutics’ drug discovery program in spinal muscular atrophy, a genetic disorder that causes muscle weakness. Roche will pay $30 million for the program, which includes three small molecules currently in preclinical development. The Swiss firm could also make up to $460 million in milestone payments. PTC developed the program in partnership with the SMA Foundation, which will remain active in the collaboration.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X